Purdue Flexes Mid-Sized Muscle
Executive Summary
One big drug is dramatically expanding the ambitions of family-owned Purdue. Now the mid-sized firm is aggressively pursuing in-licensing opportunities and building its own research capacity. Its size and private status allow it to craft flexible terms for a broad range of drugs, without worrying about Wall St. But can this inward focused company adapt to the more public requirement of its aggressive growth plans?
You may also be interested in...
Tramadol Reformulations Highlight Pain Challenges and Opportunities
While reformulating existing drugs can sometimes look like a low risk opportunity, since active substances are already deemed safe and effective, the task is often more complex. The race to develop extended release versions of the now-generic opioid tramadol showcase these technological, clinical and regulatory challenges, while demonstrating that for those who succeed, the upside can be great. A look at Pudue's deal with Labopharm and JNJ's deal with Biovail.
Tramadol Reformulations Highlight Pain Challenges and Opportunities
While reformulating existing drugs can sometimes look like a low risk opportunity, since active substances are already deemed safe and effective, the task is often more complex. The race to develop extended release versions of the now-generic opioid tramadol showcase these technological, clinical and regulatory challenges, while demonstrating that for those who succeed, the upside can be great. A look at Pudue's deal with Labopharm and JNJ's deal with Biovail.
MedPointe's Private Dilemma
MedPointe was born via the leveraged buy-out of an old, private pharmaceutical company, Carter-Wallace. Accepting financial strictures was part of the deal; the company must remain profitable. This increases the challenge for the "founders," seasoned pharma execs intent on leveraging the infrastructure they overhauled, to created an in-licensing based marketing powerhouse. Beyond competing with bigger pharma marketers, management's challenge remains bringing in new assets affordably.